Montis Biosciences

Executive Summary

Montis Biosciences is a Belgian biotechnology company developing next-generation antibody therapeutics that uniquely target the dual biology of complement C1q. By simultaneously modulating the complement cascade and myeloid cell functions, its platform addresses neuroinflammatory, autoimmune, and neurodegenerative diseases. The company is also advancing an oncology program targeting CD93 in lung squamous cell carcinoma. Since its founding in 2021, Montis has remained in pre-clinical stage, and as of early 2026, it has not disclosed significant funding or partnerships. The company's differentiated approach could offer novel treatment options where complement dysregulation is central, but early-stage risk remains high due to lack of clinical data and financial transparency.

Upcoming Catalysts (preview)

• H2 2026Release of preclinical efficacy data for lead C1q program in neuroinflammatory models30% success
• H1 2027Announcement of Series A financing or strategic partnership50% success
• 2027Initiation of IND-enabling studies for oncology candidate (CD93)40% success